Sgt-94 is an anti-transferrin receptor antibody-engineered liposome encapsulated with a Rb94 plasmid DNA, representing a clinical perspective in phase I in patients with neoplasm (NCT01517464) [143]. Here, TFRC is linked to neoplasm.